Biomea Fusion Announces Appointment of Juan Pablo Frías, M.D. as Chief Medical Officer - Biomea Fusion (NASDAQ:BMEA)
Industry veteran and prominent diabetes clinical development expert to oversee Biomea's progressing clinical development of novel covalent menin inhibitor BMF-219 in type 2 and type 1 diabetesSteve Morris, M.D., will